Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study

Figure 2

Bioinformatics analysis-based prediction of target genes of dehydrovomifoliol involved in NAFLD treatment. (a) A heat map of the expression of DEGs in the GSE73500 dataset. (b) A volcano plot of the expression of DEGs in the GSE73500 dataset. Green dots indicate downregulated genes, red dots indicate upregulated genes, and gray dots indicate genes with no significant difference. (c) A heat map of the expression of DEGs in the GSE89632 dataset. (d) A volcano plot of the expression of DEGs in the GSE89632 dataset. Green dots indicate downregulated genes, red dots indicate upregulated genes, and gray dots indicate genes with no significant difference. (e) Venn diagram of the target genes from the PharmMapper database, DEGs from the GSE73500 and GSE89632 datasets, and NAFLD-related genes from the GeneCards database. Seven target genes of dehydrovomifoliol in NAFLD treatment were obtained.

(a)

(b)

(c)

(d)

(e)